This study was designed to assess the effect of Centratherum anthelminticum seeds administration on blood and serum risk factor markers in type 2 diabetic (T2D) patients using metformin. It was a randomized non-blinded, controlled, 3month trial. T2D patients were registered from Sindh Government Hospital New Karachi, Karachi. There were 3 groups, DT (Diabetic Test, n=20), DC (Diabetic Control, n=20) HC (Healthy Control n=20, healthy individuals of similar age were selected). DC (metformin 500mg), DT (capsule of C. anthelminticum seeds powder CAPca + metformin 500mg each) and HC (CAPca 500mg) were given daily. Fasting blood glucose, body weights were monitored weekly while blood samples were collected on first and final day of the trial for biochemistry. Administration of CAPca showed significant decrease in % glycaemia (p<0.0001) and % Hb glycosylation (p<0.05) values. Serum risk factor markers including direct bilirubin & uric acid (p<0.01), creatine kinase & alanine aminotransferase (p<0.0001) and creatinine (p<0.05) were reduced significantly. CAPca administration improved blood and serum markers in healthy volunteers too. These improved blood & serum markers in T2D patients indorsed synergistic effect of CAPca with metformin to manage secondary challenges of T2D.